Laurent et al (14) reviewed a large cohort of 38 cases of ALK+ DLBCL and observed that the majority of patients experienced an aggressive clinical course, with a 5-year survival rate of 25% following treatment with the CHOPE regimen. Here, ALK is linked to diffuse large B-cell lymphoma.